Leptin as a new diagnostic tool in chronic heart failure

被引:50
作者
Schulze, PC
Kratzsch, J
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Cardiovasc Div, Boston, MA 02115 USA
[2] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-7010 Leipzig, Germany
关键词
leptin; chronic heart failure; atherosclerosis; risk; biomarker;
D O I
10.1016/j.cccn.2005.05.019
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Leptin, the product of the ob-gene, regulates cellular homeostasis and glycemic control. While initially described as an adipocyte-derived protein with expression and secretion restricted to adipose tissue, recent reports have shown local expression of leptin in several tissues including the skeletal muscle, heart, vessels and brain. Leptin acts through the different isoforms of its receptor which are ubiquitously expressed and can be detected in endothelium, vascular smooth muscle and tnyocardium. In addition to its metabolic effects, leptin has distinct effects in the cardiovascular system leading to increased production of proinflammatory cytokines and oxidative stress, vascular remodeling and neointima formation as well as cardiomyocyte hypertrophy. Notably, recent clinical studies have linked serum levels of leptin to the occurrence of cardiovascular events such as myocardial infarction and stroke suggesting that leptin promotes pro-atherogenic vascular mechanisms. In contrast, less is known about the role and effects of leptin in the setting of chronic heart failure. We here review the current knowledge on cardiovascular effects of leptin and discuss its potential as a new therapeutic tool in chronic heart failure. (c) 2005 Blsevier B.V. All rights reserved.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 113 条
[1]   Leptin [J].
Ahima, RS ;
Flier, JS .
ANNUAL REVIEW OF PHYSIOLOGY, 2000, 62 :413-437
[2]   Pathophysiological role of leptin in obesity-related hypertension [J].
Aizawa-Abe, M ;
Ogawa, Y ;
Masuzaki, H ;
Ebihara, K ;
Satoh, N ;
Iwai, H ;
Matsuoka, N ;
Hayashi, T ;
Hosoda, K ;
Inoue, G ;
Yoshimasa, Y ;
Nakao, K .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (09) :1243-1252
[3]   Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss [J].
Alpert, MA ;
Terry, BE ;
Mulekar, M ;
Cohen, MV ;
Massey, CV ;
Fan, TM ;
Panayiotou, H ;
Mukerji, V .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (06) :736-740
[4]  
Anker SD, 1997, EUR HEART J, V18, P259
[5]   Wasting as independent risk factor for mortality in chronic heart failure [J].
Anker, SD ;
Ponikowski, P ;
Varney, S ;
Chua, TP ;
Clark, AL ;
WebbPeploe, KM ;
Harrington, D ;
Kox, WJ ;
PooleWilson, PA ;
Coats, AJS .
LANCET, 1997, 349 (9058) :1050-1053
[6]  
Anker SD, 1997, CIRCULATION, V96, P526
[7]   Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone [J].
Anker, SD ;
Volterrani, M ;
Pflaum, CD ;
Strasburger, CJ ;
Osterziel, KJ ;
Doehner, W ;
Ranke, MB ;
Poole-Wilson, PA ;
Giustina, A ;
Dietz, R ;
Coats, AJS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (02) :443-452
[8]   Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis [J].
Atkinson, LL ;
Fischer, MA ;
Lopaschuk, GD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (33) :29424-29430
[9]   Leptin [J].
Auwerx, J ;
Staels, B .
LANCET, 1998, 351 (9104) :737-742
[10]   Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice [J].
Barouch, LA ;
Berkowitz, DE ;
Harrison, RW ;
O'Donnell, CP ;
Hare, JM .
CIRCULATION, 2003, 108 (06) :754-759